Polyoxyl 60 hydrogenated castor oil free nanosomal formulation of immunosuppressant Tacrolimus: Pharmacokinetics, safety, and tolerability in rodents and humans

International Immunopharmacology

Volumn 10, Issue 3, 2010, Pages 325-330

  Ali, Shoukath M ^a   Ahmad, Ateeq ^a   Sheikh, Saifuddin ^a   Ahmad, Moghis U ^a   Rane, Rajendar C ^b   Kale, Prashant ^c   Paithankar, Mahesh ^d   Saptarishi, Dipak ^d   Sehgal, Ashish ^d   Maheshwari, Kirti ^d   Ahmad, Imran ^a  

^a Jina Pharmaceuticals Inc   (United States)

^b Intas Pharmaceuticals Ltd   (India)

^c Lambda Therapeutic Research Limited   (India)

^d Astron Research Limited   (India)

Author keywords

Drug delivery; Immunosuppression; Lipid; Nanosomes; Tacrolimus; Transplantation

Indexed keywords

CASTOR OIL; POLYOXYL 60 HYDROGENATED CASTOR OIL; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTRON MICROSCOPY; EPIGASTRIC PAIN; FEMALE; FREEZE FRACTURE; HUMAN; HYDROGENATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; ANIMALS; AREA UNDER CURVE; CASTOR OIL; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EXCIPIENTS; FEMALE; FREEZE FRACTURING; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDICATORS AND REAGENTS; LYMPHOCYTE COUNT; MALE; MASS SPECTROMETRY; MICE; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS; YOUNG ADULT;

EID: 77149164770     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.12.003     Document Type: Article

References (16)

1. Griffith B.P., Bando K., Hardesty R.L., Armitage J.M., Keenan R.J., Pham S.M., Paradis I.L., Yousem S.A., Komatsu K., Konishi H., Fung J.J., and Starzl T.E. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation 57 (1994) 848-851
2. Knoop Thiry C.P., Saint-Marcoux F., Rousseau A., Marquet P., and Estenne M. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. Am J Transpl 5 (2005) 1477-1482
3. Venkataramanan R., Jain A., Cadoff E., Warty V., Iwasaki K., Nagase K., et al. Pharmacokinetics of FK506: preclinical and clinical studies. Transplant Proc 22 Suppl 1 (1990) 52-56
4. Beysens A.J., Wijnen R.M., Beuman G.H., van der Heyden J., Kootstra G., and van As H. Monitoring in plasma or whole blood. Transplant Proc 23 (1991) 2745-2747
5. Okabe S. Drug eruption by solution trioxyethylene hydrogenated castor oil (HCO-60) in vitamin K2. Nippon Hifuka Gakkao Zasshi-Jpn J. Dermatol. 91 (1981) 759-762
6. Ohta S., Iwane S., Katsura T., Shimada M., and Hayashi S. Leukocytosis induced by BH-AC administration. Allergic reaction to vastor oil HCO-60. A case report. Rinsho ketsueki-Jpn J Clin Hematol 26 (1985) 555-559
7. Ninomiya H., Hanada T., Nakazawam M., Aoki T., Shubuya A., Nagasawa T., and Abe T. Immunological erythblastopenia induced by HCO-60 as a solvent of enocitabine (BH-AC). Nippon Ketseki Gakkai Zasshi Acta Haematol Jpn 50 (1987) 777-783
8. ®-Package Insert 2006, Astellas Pharma, US.
9. Cañadas O., Guerrero R., García-Cañero R., Orellana G., Menéndez M., and Casals C. Characterization of liposomal Tacrolimus in lung surfactant-like phospholipids and evaluation of its immunosuppressive activity. Biochemistry 43 (2004) 9926-9938
10. Moffat S.D., McAlister V., Calne R.Y., and Metcalfe S.M. Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. Transplantation 67 (1999) 1205-1208
11. Lee M.-J., Straubinger R.M., and Jusko W.J. Physiochemical, pharmacokinetic and pharmacodynamic evaluation of liposomal Tacrolimus (FK506) in rats. Pharmaceutical Res 12 (1995) 1055-1059
12. Zhang Q., Simpson J., and Aboleneen H.I. A Specific method for the measurement of tacrolimus in human whole blood by liquid chromatography/tandem mass spectrometry. Ther Drug Monit 19 4 (1997) 470-476
13. Taylor P.J., Jones A., Balderson G.A., Lynch S.V., Norris R.L., and Pond S.M. Sensitive specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 42 (1996) 279-285
14. Jusko W.J. Anaysis of tacrolimus (FK506) in relation to therapeutic drug monitoring. Drug Monit 17 6 (1995) 596-601
15. Chougule M., Padhi B., and Misra A. Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization and pulmonary pharmacokinetics. Int J Nanomed 2 4 (2007) 675-688
16. Matsuura M., Imayoshi T., Chiba K., and Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats. Inflamm Res 49 (2000) 404-410